medigraphic.com

2012, Number 2

<< Back Next >>

Cir Cir 2012; 80 (2)

Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome

Castro-Martínez MG, Banderas-Lares DZ, Ramírez-Martínez JC, Escobedo-de la Peña J

Language: Spanish
References: 19
Page: 128-132
PDF size: 159.54 Kb.


ABSTRACT

Background: Nonalcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease. Metabolic syndrome (MetS) is an important predictor of NAFLD. Due to the increase of MetS in Mexico, a population-based cross-sectional study was conducted to estimate the prevalence of NAFLD.
Methods: One hundred ninety eight subjects with MetS were randomly selected from 1006 subjects and were invited to partipate in the estimation of the prevalence of NAFLD. MetS was diagnosed following the criteria of the National Cholesterol Education Program (ATPIII-NCEP). Abdominal ultrasound was performed and left, right and caudate lobes were assessed according to size, echogenicity and hepatic borders. NAFLD was classified as mild, moderate and severe according to its echogenicity and visualization of the diaphragm and intrahepatic vessel borders. Prevalence of NAFLD was estimated with 95% confidence intervals (95% CI).
Results: Included in the study were122 males (63.2%) and 71 females (36.8%). Prevalence of NAFLD was 82.9% (95% CI 77.6–88.2%). Prevalence was higher in males (p = 86.9%; 95% CI 80.9–92.9%) than in females (p = 76.1%; 95% CI 66.1–86.0%). There were no age differences. A higher proportion of patients had mild (52.3%) or moderate (22.3%) NAFLD and in only 16 patients was NAFLD severe (8.3%).
Conclusions: The observed prevalence is alarming because 8/10 subjects with MetS had NAFLD in any stage. Health-related measures oriented to decrease the incidence of the MetS will have a favorable impact on the occurrence of NAFLD.


REFERENCES

  1. Argo CK, Caldwell SH. Epidemiology and natural history of nonalcoholic steatohepatitis. Clin Liver Dis 2009;13:511-531.

  2. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Clev Clin J Med 2008;75:721-728.

  3. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-728.

  4. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM, Franco A. High prevalence of metabolic syndrome in Mexico. Arch Med Res 2004;35:76-81.

  5. Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, et al. Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol 2009;8:52.

  6. Lizardi-Cervera J, Becerra Laparra I, Chávez-Tapia NC, Ramos Ostos ME, Uribe Ezquivel M. Prevalencia de hígado graso no alcohólico y síndrome metabólico en población asintomática. Rev Gastroenterol Mex 2006;71:454-459.

  7. Álvarez-Martínez HE, Pérez-Campos E, Leyva-Bohórquez P. Prevalencia de esteatohepatitis no alcohólica en adultos con síndrome metabólico en Oaxaca. Gac Med Mex 2005;141:7-12.

  8. Roesch-Dietlen F, Dorantes-Cuéllar A, Carrillo-Toledo MG, Martínez-Sibajar C, Rojas-Carrera S, Bonilla-Rojas S, et al. Frecuencia del hígado graso no alcohólico en un grupo de pacientes con síndrome metabólico estudiado en la ciudad de Veracruz. Rev Gastroenterol Mex 2006;71:446-452.

  9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.

  10. American Diabetes Association. Standards of Medical Care in Diabetes 2010. Diabetes Care 2010;33:S11-S-61.

  11. Charatcharoenwitthaya P. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007;11:1137-1154.

  12. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007;22:293-303.

  13. Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Int Med 2008;19:75-82.

  14. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008;14:185-192.

  15. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923.

  16. Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008;31:562-568.

  17. Tsai CH, Li TC, Lin CC. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J 2008;101:900-905.

  18. Corner MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.

  19. Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004;27:2057-2066.




2020     |     www.medigraphic.com